Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6-36 months of androgen deprivation therapy and radiotherapy: a systematic literature review.

Studied

A systematic review of testosterone monitoring, recovery and replacement after androgen-deprivation therapy plus radiotherapy for prostate cancer.

Who / model

Twenty-nine studies concerning intermediate- or high-risk localized prostate cancer. Searches ran through May 2026; total participant numbers are not given in the abstract.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Baseline testosterone predicted recovery rather than cancer outcomes. Lower testosterone during treatment was associated with better cancer outcomes. Recovery varied, often taking years to normalize, with longer treatment, older age and lower starting testosterone associated with slower recovery.

Limits

Evidence about testosterone replacement after curative treatment was very limited and observational, particularly in high-risk patients. It does not establish recurrence safety.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary